Holen Sie sich die Stockscreener-App
36.80
0.78%
-0.29
Vorhandelsmarkt:
37.01
0.21
+0.57%
Schlusskurs vom Vortag:
$37.09
Offen:
$37.215
24-Stunden-Volumen:
702.43K
Relative Volume:
0.60
Marktkapitalisierung:
$3.88B
Einnahmen:
$18.07M
Nettoeinkommen (Verlust:
$-496.39M
KGV:
-7.1689
EPS:
-5.1333
Netto-Cashflow:
$-419.52M
1W Leistung:
+0.08%
1M Leistung:
-5.88%
6M Leistung:
-14.14%
1J Leistung:
+22.22%
1-Tages-Spanne:
$36.64
$37.80
1-Wochen-Bereich:
$33.89
$37.80
52-Wochen-Spanne:
$25.83
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
36.80 | 3.91B | 18.07M | -496.39M | -419.52M | -5.1333 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 - Yahoo Finance UK
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? - The Motley Fool
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics shares jump on robust PALSONIFY uptake and encouraging trial results - MSN
Precision Trading with Crinetics Pharmaceuticals Inc. (CRNX) Risk Zones - Stock Traders Daily
CRNX Maintained by Evercore ISI Group -- Price Target Lowered to $88 - GuruFocus
T. Rowe Price (NASDAQ: CRNX) reports 5.1% holding in Crinetics - Stock Titan
Wellington Management Group (CRNX) reports 7.79% beneficial stake in Crinetics - Stock Titan
Driehaus reduces holding in Crinetics Pharmaceuticals (NASDAQ: CRNX) to 6.11% - Stock Titan
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Q1 2026 Revenue Growth And Wider Net Loss - Sahm
Industry Analysts Just Upgraded Their Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Revenue Forecasts By 11% - Yahoo Finance
Crinetics Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:CRNX) 2026-05-12 - Seeking Alpha
Crinetics outlines plan to exceed 75% Palsonify coverage by end of Q3 2026 while funding operations into 2030 - MSN
Twilio To Rally Over 25%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
What is HC Wainwright's Estimate for CRNX Q2 Earnings? - MarketBeat
Lifesci Capital Has Bullish Estimate for CRNX Q2 Earnings - MarketBeat
Earnings call transcript: Crinetics Pharma Q1 2026 revenue beats forecast - Investing.com India
Earnings call transcript: Crinetics Pharma Q1 2026 revenue beats forecast By Investing.com - Investing.com Nigeria
CRNX Maintained by Oppenheimer -- Price Target Lowered to $84.00 - GuruFocus
Oppenheimer Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $84.00 - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Oppenheimer Adjusts Crinetics Pharmaceuticals PT to $84 From $87, Maintains Outperform Rating - marketscreener.com
Oppenheimer cuts Crinetics stock price target on revenue beat By Investing.com - Investing.com Canada
HC Wainwright Has Negative Estimate for CRNX FY2030 Earnings - MarketBeat
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Momentum - Yahoo Finance
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2026 Earnings Call Transcript - Insider Monkey
Crinetics Pharmaceuticals (NASDAQ:CRNX) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Crinetics Pharmaceuticals (CRNX) Cash Burn And EPS Loss Reinforce Bearish Profitability Concerns - Sahm
Crinetics Q1 2026 slides: Palsonify launch drives 26% revenue beat By Investing.com - Investing.com South Africa
Crinetics (CRNX) Q1 2026 Earnings Transcript - AOL.com
Crinetics Pharmaceuticals Down Over 14%, on Pace for Largest Percent Decrease Since January 2025 -- Data Talk - Moomoo
CRNX Maintained by Citizens -- Price Target Lowered to $95.00 - GuruFocus
Crinetics Pharmaceuticals, Inc. (CRNX) reports Q1 loss, beats revenue estimates - MSN
Crinetics Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Citizens cuts Crinetics stock price target to $95 on valuation - Investing.com UK
Citizens cuts Crinetics stock price target to $95 on valuation By Investing.com - Investing.com South Africa
Crinetics (CRNX) Reports Strong Q1 Revenue Growth - GuruFocus
Crinetics Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Transcript : Crinetics Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 07, 2026 - marketscreener.com
Crinetics Q1 2026 slides: Palsonify launch drives 26% revenue beat - Investing.com
Earnings call transcript: CRINETICS PHARMACEUTICALS Q1 2026 beats revenue forecasts - Investing.com Australia
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.98%
1.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):